{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:30:54Z","timestamp":1793359854661,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dialogues in Health"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.dialog.2026.100343","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T15:32:46Z","timestamp":1787153566000},"page":"100343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Early mineralocorticoid receptor antagonism for end-organ protection in hypertension: Implications for disparities and rethinking the timing paradigm"],"prefix":"10.1016","volume":"9","author":[{"given":"Camellus O.","family":"Ezeugwu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dialog.2026.100343_bb0005","first-page":"e13","article-title":"2017 ACC\/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.dialog.2026.100343_bb0010","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH Guidelines for the management of arterial hypertension","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"10.1016\/j.dialog.2026.100343_bb0015","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood pressure control","volume":"373","author":"SPRINT Research Group","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dialog.2026.100343_bb0020","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa2111437","article-title":"Intensive blood pressure control in older patients with hypertension (STEP)","volume":"385","author":"Zhang","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.dialog.2026.100343_bb0025","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.amjmed.2012.04.008","article-title":"Hypertension and chronic kidney disease progression: why the suboptimal outcomes?","volume":"125","author":"Bidani","year":"2012","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.dialog.2026.100343_bb0030","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1161\/HYPERTENSIONAHA.123.21708","article-title":"Myocardial interstitial fibrosis in hypertensive heart disease: from mechanisms to clinical management","volume":"81","author":"Gonz\u00e1lez","year":"2024","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.dialog.2026.100343_bb0035","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/JOE-14-0471","article-title":"Mineralocorticoid receptors in the heart: lessons from cell-selective transgenic animals","volume":"224","author":"Young","year":"2015","journal-title":"J Endocrinol"},{"issue":"1","key":"10.1016\/j.dialog.2026.100343_bb0040","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10741-005-2344-2","article-title":"Mineralocorticoid receptors: distribution and activation","volume":"10","author":"Funder","year":"2005","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.dialog.2026.100343_bb0045","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1146\/annurev-physiol-060821-013950","article-title":"Roles of mineralocorticoid receptors in cardiovascular and cardiorenal diseases","volume":"84","author":"Barrera-Chimal","year":"2022","journal-title":"Annu Rev Physiol"},{"issue":"2","key":"10.1016\/j.dialog.2026.100343_bb0050","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1161\/HYPERTENSIONAHA.118.11064","article-title":"Hypertension in Blacks: individualized therapy based on renin\/aldosterone phenotyping","volume":"72","author":"Spence","year":"2018","journal-title":"Hypertension"},{"issue":"3 Pt 2","key":"10.1016\/j.dialog.2026.100343_bb0055","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1161\/01.HYP.27.3.481","article-title":"Salt sensitivity of blood pressure in humans","volume":"27","author":"Weinberger","year":"1996","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.dialog.2026.100343_bb0060","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1161\/HYPERTENSIONAHA.122.17964","article-title":"Aldosterone as a mediator of cardiovascular damage","volume":"79","author":"Buffolo","year":"2022","journal-title":"Hypertension"},{"issue":"13","key":"10.1016\/j.dialog.2026.100343_bb0065","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1111\/bph.15708","article-title":"Mineralocorticoid receptor in cardiovascular diseases\u2014clinical trials and mechanistic insights","volume":"179","author":"Bauersachs","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"6","key":"10.1016\/j.dialog.2026.100343_bb0070","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1210\/er.2018-00139","article-title":"The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment","volume":"39","author":"Vaidya","year":"2018","journal-title":"Endocr Rev"},{"issue":"1","key":"10.1016\/j.dialog.2026.100343_bb0075","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary aldosteronism: a cross-sectional study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.dialog.2026.100343_bb0080","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.dialog.2026.100343_bb0085","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.dialog.2026.100343_bb0090","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1161\/HYPERTENSIONAHA.108.189141","article-title":"Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association","volume":"51","author":"Calhoun","year":"2008","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.dialog.2026.100343_bb0095","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41581-021-00490-8","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease \u2014 mechanistic and therapeutic effects","volume":"18","author":"Barrera-Chimal","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.dialog.2026.100343_bb0100","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.dialog.2026.100343_bb0105","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ejheart.2004.04.013","article-title":"The clinical implications of aldosterone escape in congestive heart failure","volume":"6","author":"Struthers","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.dialog.2026.100343_bb0110","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0895-7061(03)00913-0","article-title":"Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy","volume":"16","author":"Sato","year":"2003","journal-title":"Am J Hypertens"},{"issue":"18","key":"10.1016\/j.dialog.2026.100343_bb0115","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1161\/CIRCULATIONAHA.111.067918","article-title":"Aldosterone, mineralocorticoid receptor activation, and cardiovascular remodeling","volume":"124","author":"Leopold","year":"2011","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.dialog.2026.100343_bb0120","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/ajh\/hpaa137","article-title":"Aldosterone, inflammation, immune system, and hypertension","volume":"34","author":"Ferreira","year":"2021","journal-title":"Am J Hypertens"},{"issue":"1","key":"10.1016\/j.dialog.2026.100343_bb0125","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/pr.115.011106","article-title":"Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology","volume":"68","author":"Jaisser","year":"2016","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.dialog.2026.100343_bb0130","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMra000050","article-title":"Aldosterone in congestive heart failure","volume":"345","author":"Weber","year":"2001","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.dialog.2026.100343_bb0135","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/HYPERTENSIONAHA.107.095489","article-title":"Aldosterone and vascular inflammation","volume":"51","author":"Brown","year":"2008","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.dialog.2026.100343_bb0140","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000515622","article-title":"Aldosterone and mineralocorticoid receptor signaling as determinants of cardiovascular and renal injury: from Hans Selye to the present","volume":"52","author":"Epstein","year":"2021","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.dialog.2026.100343_bb0150","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.dialog.2026.100343_bb0155","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dialog.2026.100343_bb0160","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dialog.2026.100343_bb0165","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/eurheartj\/ehs257","article-title":"Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice","volume":"33","author":"Zannad","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.dialog.2026.100343_bb0170","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction (TOPCAT)","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.dialog.2026.100343_bb0175","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.dialog.2026.100343_bb0180","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dialog.2026.100343_bb0185","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.dialog.2026.100343_bb0190","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl. 1","key":"10.1016\/j.dialog.2026.100343_bb0195","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/dom.13983","article-title":"Non-steroidal mineralocorticoid antagonists: prospects for renoprotection in diabetic kidney disease","volume":"22","author":"Al Dhaybi","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.dialog.2026.100343_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105859","article-title":"Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders \u2014 new perspectives for combination therapy","volume":"172","author":"Kolkhof","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.dialog.2026.100343_bb0205","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction (DAPA-HF)","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dialog.2026.100343_bb0210","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy (CREDENCE)","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.dialog.2026.100343_bb0215","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.dialog.2026.100343_bb0220","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/ckj\/sfac234","article-title":"A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease","volume":"16","author":"Agarwal","year":"2023","journal-title":"Clin Kidney J"},{"issue":"1","key":"10.1016\/j.dialog.2026.100343_bb0225","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/ehjcvp\/pvw016","article-title":"Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives","volume":"3","author":"Pitt","year":"2017","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"9","key":"10.1016\/j.dialog.2026.100343_bb0230","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"issue":"13","key":"10.1016\/j.dialog.2026.100343_bb0235","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1111\/bph.15734","article-title":"The mineralocorticoid receptor in chronic kidney disease","volume":"179","author":"Barrera-Chimal","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"8","key":"10.1016\/j.dialog.2026.100343_bb0240","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/ejhf.1724","article-title":"Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction","volume":"22","author":"Rossignol","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.dialog.2026.100343_bb0245","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jchf.2018.01.009","article-title":"Obesity-related heart failure with a preserved ejection fraction: the mechanistic rationale for combining inhibitors of aldosterone, neprilysin, and sodium-glucose cotransporter-2","volume":"6","author":"Packer","year":"2018","journal-title":"JACC Heart Fail"},{"issue":"27","key":"10.1016\/j.dialog.2026.100343_bb0250","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1093\/eurheartj\/ehaf225","article-title":"Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease","volume":"46","author":"Kobayashi","year":"2025","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.dialog.2026.100343_bb0255","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/ehjcvp\/pvy015","article-title":"Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin-angiotensin-aldosterone system inhibitors","volume":"4","author":"Rosano","year":"2018","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"12","key":"10.1016\/j.dialog.2026.100343_bb0260","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.34067\/KID.0000000586","article-title":"The association of heart failure and edema events between patients initiating sodium zirconium cyclosilicate or patiromer","volume":"5","author":"Desai","year":"2024","journal-title":"Kidney360"},{"issue":"41","key":"10.1016\/j.dialog.2026.100343_bb0265","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","article-title":"Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.dialog.2026.100343_bb0270","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"}],"container-title":["Dialogues in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772653326000687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772653326000687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T10:36:23Z","timestamp":1793356583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772653326000687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":53,"alternative-id":["S2772653326000687"],"URL":"https:\/\/doi.org\/10.1016\/j.dialog.2026.100343","relation":{},"ISSN":["2772-6533"],"issn-type":[{"value":"2772-6533","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early mineralocorticoid receptor antagonism for end-organ protection in hypertension: Implications for disparities and rethinking the timing paradigm","name":"articletitle","label":"Article Title"},{"value":"Dialogues in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dialog.2026.100343","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100343"}}